Announcements Trials
Browse Landscape

Phase

Phase NA 6Phase 2 5Phase 3 4Phase 4 2Phase 1/2 2Phase 1 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Vomiting 2Uterine Neoplasms 1Ovarian Neoplasms 1Breast Neoplasms 1

Interventions

Dexamethasone 49Metformin 47Cyclophosphamide 42Saline Solution 38Cytarabine 34Sodium Chloride 31Bupivacaine 31Vincristine 27Propofol 25Methotrexate 25Cisplatin 25Letrozole 24Fluorouracil 24Dexmedetomidine 24Doxorubicin 23Fentanyl 22Carboplatin 22Etoposide 19Rituximab 18Morphine 18Acetaminophen 18Lidocaine 17Granulocyte Colony-Stimulating Factor 17Bevacizumab 17Prednisone 16Mercaptopurine 16Docetaxel 16Clomiphene 16Sevoflurane 15Idarubicin 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × OTHER × fosaprepitant × Clear all
NCT05841849 2023-05-03

Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 4 Not yet recruiting
1,028 enrolled
Breast

Breast Neoplasms, Vomiting

NCT01432015 2017-03-28

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

Gynecologic Oncology Associates

Phase 4 Completed
20 enrolled 5 charts
Gynecologic

Ovarian Neoplasms, Uterine Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡